ARCHIVES

Phase III Trial of Talimogene Laherparepvec Meets Response Rate Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 36 No. 3 | March 29, 2013

Download PDF Visit The Full Archive

Related Articles

Federal Cigarettes Tax Extension Approved By Senate

October 4, 1985

In Brief: Sullivan Rejects Oregon Medicaid Rationing Plan; Howe To Head National Marrow Donor Program

August 7, 1992

Jury Awards $14 Million To Medenica Patient

February 24, 1995

UICC Seeks Nominations for Mucio Athayde Prize.

January 7, 2000

In Brief: NIH Funding For Shannon Awards To Fall, Eight Institutes Decide Not To Participate

August 13, 1993

Tivozanib Trumps Sorafenib In 1st-Line Renal Cancer Study

May 25, 2012